Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 361 across all filing types
Latest filing 2026-03-11 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF TECHNOLOGY OFFICER
Board/Management Information Classification · 1% confidence The document is an official announcement from Alphamab Oncology regarding the appointment of a new Chief Technology Officer (Dr. WANG Hongwei). It details the individual's biographical information and professional background. This falls under the category of management changes, which is explicitly defined as 'Board/Management Information' (MANG).
2026-03-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory filing used by listed companies in Hong Kong to report monthly movements in securities, including share capital, share options, and treasury shares. It does not fit into specific categories like 'Annual Report' or 'Earnings Release' but is a mandatory regulatory disclosure required by the Exchange Listing Rules. Therefore, it is classified as a Regulatory Filing (RNS).
2026-03-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Stock Exchange. This is a standard regulatory filing required by the HKEX Listing Rules to report movements in securities, share capital, and treasury shares on a monthly basis. It does not fit into specific categories like 'Share Issue' (SHA) or 'Transaction in Own Shares' (POS) exclusively, as it covers a broader scope of regulatory reporting required by the exchange. Therefore, it is classified as a Regulatory Filing (RNS).
2026-02-05 English
VOLUNTARY ANNOUNCEMENT - NDA FOR FIRST-LINE TREATMENT OF BTC OF KN035 WAS ACCEPTED BY THE NMPA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Alphamab Oncology regarding the NMPA's acceptance of a New Drug Application (NDA) for a specific treatment (KN035). It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement. As it is a regulatory announcement regarding business/clinical advancement that does not fall into specific categories like M&A or Board changes, it is classified as a general regulatory filing.
2026-01-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory filing used by listed companies in Hong Kong to report monthly movements in securities, including share capital, treasury shares, and share options. Since it details specific share repurchases and changes in issued shares for the month of December 2025, it falls under the category of regulatory filings required by the Exchange Listing Rules.
2026-01-06 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It explicitly details the repurchase of 500,000 shares by Alphamab Oncology on 31 December 2025. According to the provided definitions, reports of a company buying back its own shares are classified as 'Transaction in Own Shares' (POS).
2025-12-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.